Shares of Gilead Sciences were downgraded on Monday by not one but two firms, BMO Capital and Wells Fargo. The biotech giant was downgraded by the analysts who said it is fully valued amid market enthusiasm for its drug candidate to treat COVID-19, remdesivir. BMO Capital’s Matthew Luchini downgraded the stock to market perform from … Continue reading “Gilead Sciences Gets a Downgrade from BMO Capital and Wells Fargo”
Tag: gilead sciences
Biotech & Pharma
Gilead Paid $510 Million For This Drug But Sold it For Only $3 Million
It was five years ago that Gilead Sciences Inc. paid $510 million for a deal…
August 23, 2018
Biotech & PharmaFeatured
Gilead Sciences Will Collaborate with Pfizer Over This Therapy
It was announced this week that Kite Pharma Inc., a subsidiary of Gilead Sciences, has…
January 20, 2018
Biotech & Pharma
Gilead Shares Climb Higher After Impressive HIV Drug News
Gilead traders had something to celebrate on Tuesday. The company's HIV drug has met its…
May 30, 2017
Biotech & Pharma
Medivation (MDNV) Gets Interest From Major Pharma
Medivation shares soared higher on Wednesday when a report revealed that at least five pharmaceutical…
August 18, 2016